Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Zillow Group Inc Class C — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Zillow Group Inc Class C trades at $32.1 (market cap $7.50B). The key difference: Zillow Group Inc Class C is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| ACAD | Z | |
|---|---|---|
Market Cap | $4.49B | $7.50B |
Sector | Health | Media |
52-Week High | $28.06 | $90.35 |
52-Week Low | $20.06 | $29.41 |
Enterprise Value | $3.69B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Zillow Group (Z) trades at $32.96, down 1.41% on the day, amid mixed technical signals and ongoing class action lawsuits. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and net income turning positive at $23M, though valuation remains elevated with a P/E of 131.84. Analyst consensus is a Buy with a $63 price target, but legal overhangs and negative cash flow trends present headwinds.
The outlook is cautiously optimistic given strong revenue growth and analyst support, but investment opportunities are tempered by legal risks and high valuation multiples. Key risks include lawsuit outcomes, competitive pressures, and cash flow sustainability, requiring careful monitoring of upcoming Q2 2026 earnings on August 5 for confirmation of profit trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
